Johnson & Johnson's Imaavy (nipocalizumab) approved by FDA, ushering in a new era in the treatment of myasthenia gravis

On 20254 month30, Johnson & Johnson officially announced that The Food and Drug Administration (FDA) approved its innovative monoclonal antibody therapy Imaavy (nipocalizumab, n ipocalimab-aahu) is indicated for the treatment of anti-acetylcholine receptor (AChR n>) or muscle-specific tyrosine kinase (MuSK) antibody-positive patients with generalized myasthenia gravis (gMG). This breakthrough marks Imaavy becoming the first approved neonatal Fc receptor (FcRn) blocker, providing a new treatment option for gMG patients. Currently, multiple regulatory agencies around the world are also actively reviewing the drug’s marketing application and are expected to further expand its scope of application.

Myasthenia gravis is an autoimmune disease in which the patient's body mistakenly produces antibodies that attack the proteins at the junction of nerves and muscles, causing muscle signal transmission to be blocked, manifesting as progressive muscle weakness. Initial symptoms are often concentrated in the eyes, but approximately 85% of patients develop systemic symptoms, with difficulty swallowing and speaking. Traditional therapies include acetylcholinesterase inhibitors, immunosuppressants, and plasma exchange, but some patients are intolerant or have limited efficacy. Imaavyby targeting FcRnblocking the recycling of IgG antibodies, effectively reducing the levels of pathogenic autoantibodies, demonstrating a unique therapeutic mechanism.

ImaavyAs a monoclonal antibody, it can specifically bind to the neonatal Fc receptor, prevent the reabsorption of immunoglobulin G (IgG), and promote the degradation of pathogenic antibodies in cells. Clinical data shows that the drug can reduce total IgG levels by up to 75%, significantly reduce anti-AChR and anti-MuSK and other pathogenic antibodies, while also targeting IgEImmune components such as , IgA and IgM have no significant impact, ensuring the normal operation of the patient's immune system. The pivotal clinical trial of Vivacity-MG3 enrolled 199 patients with gMG and randomized them to receive Imaavy or placebo. The trial results showed that patients in the Imaavy group had significant improvements in myasthenia gravis daily living ability scores (MG-ADL) and quantitative myasthenia scores (QMG), and the efficacy remained stable.

In addition, Imaavy’s efficacy in adolescents has also been verified. The VIBRANCE-MG study showed that patients aged 12 to 18 also achieved a significant decrease in serum IgG and symptom relief. In terms of safety, Imaavy is generally well tolerated. Common side effects include respiratory infection, peripheral edema and muscle spasm, but the incidence of serious adverse reactions is low. In summary, Imaavy brings new treatment hope to patients with myasthenia gravis, especially those who have insufficient response to traditional treatments, providing more precise and safe medication options.

References:Johnson & Johnson receives FDA approval for IMAAVY™ (nipocalimab-aahu), a new FcRn blocker offering long-lasting disease control in the broadest population of people living with generalized myasthenia gravis (gMG). News release. Johnson & Johnson. April 30, 2025. Accessed April 30, 2025.